10 Best Biotech Stocks to Buy According to Mark Lampert's Biotechnology Value Fund
In this article, we discuss the 10 best biotech stocks to buy according to Mark Lampert.
Established in 1993, Biotechnology Value Fund is a private investment partnership headquartered in San Francisco. Specializing in fundamentally driven public biotechnology investments, BVF has consistently focused on building concentrated, long-term positions in small-cap biotechnology companies.
Mark Lampert, founder and president of the Biotechnology Value Fund, previously held the position of Vice President at the investment banking firm Oppenheimer & Co. in New York. He also established Biotechnology Royalty Corp., a venture that aggregated biotechnology patent royalties from universities. Lampert led business development at Cambridge NeuroScience and served as Assistant to the President of NutraSweet Company, a subsidiary of G.D. Searle & Co. His career began at the Boston Consulting Group. Lampert holds an AB Degree in chemistry from Harvard College and an MBA Degree from Harvard Business School.
Biotechnology Value Fund L.P. has secured $1.51 billion in investments from 27 investors, with a minimum investment requirement of $25 million.
